Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Short, K Detweiler, Rajkumar, SV, Larson, D, Buadi, F, Hayman, S, Dispenzieri, A, Gertz, M, Kumar, S, Mikhael, J, Roy, V, Kyle, RA, Lacy, MQ
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3736849/
https://ncbi.nlm.nih.gov/pubmed/21350560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2011.29
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares